InvivoSciences

InvivoSciences is a private, preclinical-stage biotech founded in 2008 and based in Madison, Wisconsin. The company has developed a proprietary, automated platform for generating and functionally testing patient-derived 3D micro-heart tissues, positioning itself as both a technology provider for pharmaceutical partners and a therapeutics developer. Its core value proposition is using human-relevant, physiologically complex tissue data to improve the predictability of drug efficacy and safety, particularly for heart failure and cardiotoxicity, thereby aiming to reduce the high cost and failure rate of clinical trials. The company appears to be pre-revenue, supported by grants and investors.

Automated, scalable platform for generating and functionally testing 3D engineered micro-human heart tissues (NuHeart™) derived from patient-specific and gene-edited iPSCs. Integrates tissue handling automation, high-throughput biomechanical phenotyping assays, and AI-driven computational biology.

InvivoSciences competes in the growing 'organ-on-a-chip' and 3D tissue engineering space with companies like Emulate, CN Bio, and TARA Biosystems (focused on cardiac tissues). It also faces competition from larger CROs offering standard cardiac safety testing (e.g., hERG assay) and other stem cell-based service providers. Its differentiation lies in its full-stack automation, focus on high-throughput functional phenotyping (biomechanics), and integrated AI/ML approach.